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Animal models of anxious disorders found in humans, such as panic disorder and posttraumatic stress disorder, usually include
spontaneousand conditionedfearthattriggersescapeandavoidance behaviors.Thedevelopment ofapanicdisordermodelwitha
learned component should increase knowledge of mechanisms involved in anxiety disorders. In our ethological model of extreme
anxiety in the rat, forced apnea was combined with cold water vaporization in an inescapable situation. Based on the reactions of
vehicle controls, behaviors involved in paroxysmic fear were passive (freezing) and active (jumping) reactions. Our results show
that subchronic ﬂuoxetine (5mg/kg, IP, 21 days) and imipramine (10mg/kg, IP, 14 days) administration alleviated freezing and
jumpingbehaviors,whereasacuteﬂuoxetine(1mg/kg,IP)provokedoppositeeﬀects.Acutelowdoseofdiazepam(1mg/kg,IP)was
not eﬀective, whereas the higher dose of 3mg/kg, IP, and clonazepam (1mg/kg, IP) only had an eﬀect on jumping. Paroxysmic fear
generated in this experimental condition may therefore mimic the symptomatology observed in patients with anxiety disorders.
1.Introduction
Rodents’ defensive behaviors are often studied in relation
to human psychopathology, such as generalized anxiety
disorder (GAD), panic disorder (PD), and posttraumatic
stressdisorder(PTSD).Thesebehaviorsconsistofimmediate
defensive reactions connected with the ﬂight or ﬁght system
and in anticipatory defensive behaviors, such as risk assess-
ment and neophobic responses [1].
There seems to be a relationship between risk assessment
and GAD, on one hand, and escape behaviors and PD on
the other [2–4] .W h e r e a se s c a p eb e h a v i o r st e n dt oo c c u r
in relation to a proximal threat, freezing is connected with
distant threats. Both reactions allow a remotely located
prey to avoid being detected and to prepare ﬂight or ﬁght
responses when confronted with a predator [5–7]. It is
noteworthy that wild rodents tend to ﬂee, while laboratory-
bred rats tend to freeze [8]. Escape is recognized as the most
relevant equivalent of panic attacks in the mouse defensive
test battery (MDTB) [2], the unstable elevated exposed plus-
maze (UEEPM) [9, 10], and the elevated T-maze [11]. This
behavior is also used in the model of dorsal periaqueductal
gray stimulation (dPAG), which appears as a largely valid
model for panic [12–17]. Moreover, recent studies using
chemical or electrical stimulation, such as inhibition of
dorsomedial hypothalamus [18, 19] and stimulation of
dPAG, suggest that these structures are involved in anxiety
disorders [20–25].
Subchronic administration of ﬂuoxetine (FLX), a pani-
colytic agent in humans, reduced freezing caused by dPAG
[26] and contextual fear conditioning [27]. Flight is a crucial
response during confrontations with a predator [28]a n d2 Depression Research and Treatment
constrainingenvironments,forexample,inanaturaldisaster
[1]. When confronted with earthquakes, ﬁres, or ﬂoods,
panic can be predominant [29–31]. Following Caroline and
Robert Blanchard’s work on the visible burrow system [28]
and the MDTB [32], we propose a constraining environment
with a sudden rise of water level akin to ﬂooding of a
burrow and underwater trauma-induced stress [33]. Near
drowning elicited a more severe response than exposure to a
predator’s scent [34]. This tangible life-threatening situation
may model acute and chronic reactions to stress.
Several data are consistent with our new model. For
e x a m p l e ,B o u w e ra n dS t e i ns h o w e da na s s o c i a t i o nb e t w e e n
PD and a traumatizing suﬀocation event [35]. Severson
et al. indicate that midbrain 5-hydroxytryptamine (5-HT)
neurons are central pH chemoreceptors [36] and patients
with PD have a hypersensitive chemoreceptor system [37]
andpersistentrespiratorydiﬃculties[38].Moreover,Bouton
et al. emphasize the role of conditioning in the development
of PD [39].
The present study provides a new ethological model of
escape and freezing attempts in rats due to suﬀocation fear.
The primary aim of our study was to evaluate active
(escape attempts) and passive (immobility/freezing) re-
sponses to rising water levels and to determine the eﬃcacy
of antipanic or anxiolytic agents. FLX is a selective 5-
HT reuptake inhibitor and imipramine (IMI) a combined
noradrenaline and 5-HT reuptake inhibitor both used for
treating chronic anxiety disorders, such as PD [40–43]
and PTSD [44–47]. Contrary to their panicolytic eﬀects
after chronic treatment, 5-HT reuptake blockers sometimes
cause a panicogenic eﬀect after acute administration [48–
50]. Diazepam (DZP) was also tested for its value in treat-
ing GAD [51, 52], but to a lesser extent PD and PTSD.
Finally, clonazepam (CZP), a high-potency benzodiazepine,
is frequently used in the treatment of PD because of its rapid
action onset and its good tolerability [53, 54].
2.MaterialsandMethods
2.1. Animals. Naive male Wistar/Han rats, weighing 280–
300g at testing onset, were obtained from Harlan (The
Netherlands). Prior to testing, the rats were housed in a reg-
ulated environment (humidity 50 ± 5%; temperature 22 ±
2◦C; lights on 20:00–08:00). They were allowed free access
to food (food pellets 2016, Teklad, USA) and tap water ad
libitum. After an acclimatization period of 7 days, the rats
wereweighedandrandomlydistributedintreatmentgroups.
The present protocol respects the guidelines provided by the
ASAB Ethical Committee for the treatment of animals in
behavioral research and teaching (Animal Behavior 2006, 71,
245–253), by the Canadian Council on Animal Care (Guide
to the Care and Use of Experimental Animals: Vol. 1, 2nd
Edn., 1993, vol. 2, 1984), and by the European Communities
Council Directive of 24 November 1986 (86/609/EEC).
2.2. Drugs. FLX, IMI, DZP, and CZP were purchased from
Sigma, France. All drugs were administered in a volume of
1mL/kg body weight. Separate groups of animals were used
in the evaluation of aversive behaviors. The eﬀects of FLX
(5mg/kg, IP) and IMI (10mg/kg, IP) were assessed after
subchronic administration of 21 and 14 days, respectively.
On test day, FLX and IMI were administered 30min before
testing. DZP (1 and 3mg/kg, IP), CZP (1mg/kg, IP), and
FLX (10mg/kg, IP) were assessed after acute administration
30min before testing. Doses were chosen on the basis of
previousresultsinanxietyorpanicmodels:forDZP[26,55],
CZP [3], FLX [18, 55], and IMI [56, 57]. FLX and IMI were
dissolved in a 0.9% saline solution, DZP and CZP in a 40%
propylene glycol-10% ethanol vehicle. The control groups
were given a 0.9% saline solution for experiments with FLX
and IMI and a 40% propylene glycol-10% ethanol solution
for DZP and CZP.
2.3. Apparatus. The apparatus consisted of a transparent
Plexiglas cylinder (diameter 20cm, height 60cm) placed on
a glass plate. Above the cylinder protruded a shower pommel
connected to a tap for water delivery at 15◦C. In the “Inter-
mittent cold water swim stress” paradigm, Christianson and
Drugan [58] used this temperature and their pilot studies
indicated that 15◦C was the lowest temperature that did not
harm the rats’ health. In the “Stress by immersion in cold
water” Retana-M´ arquez et al. model [59], rats were placed in
a tank of water at the same temperature.
Two types of cylinders were employed. In habituation
and test sessions, the cylinder contained a hole, allowing
water drainage and the possibility of jumping (height of
water level 10cm). In conditioning sessions (see below),
water was accumulated as the hole was closed up.
2.4. Procedure. The paradigm comprised 6-test sessions of
6min: two habituation sessions (morning and afternoon of
day 1), two conditioning sessions (morning and afternoon of
day 2), and two test sessions (baseline before treatments and
test after treatment administration) (Figure 1). The baseline
session took place in the morning of day 3, and the test
session was held either in the morning of day 4 for acute
assessment or a few days later, also in the morning, for
subchronic assessment.
In the habituation session, the rat was placed inside the
dry cylinder and water was delivered during a 2 to 5min
period on the glass plate beside the cylinder. The rat was left
for an additional min and then returned to its home cage
(Figure 1(a)).
In the conditioning session, the rat was placed inside the
dry cylinder again for 1min. During the following 3min,
water was jet propulsed on the glass plate. From the fourth
min on, water was vaporized on the rat for 90s. Water
delivery was then stopped and the rat underwent a 30s
period of partial apnea by closing the top of the cylinder
with a perforated lid. The time spent underwater was based
on the “underwater procedure” described in Richter-Levin’s
underwater trauma model [33], in which rats swim for
1min in a water maze [60] without an escape platform and
then are forcibly held under water for 30s by a metal net.
In our model, at the end of the partial apnea phase, the
rat was dried oﬀ with paper towels and then returned toDepression Research and Treatment 3
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Figure 1: Schematic representation of the procedure used for assessment of behavioral responses. (a) Habituation session in perforated
cylinder. (b) Conditioning session in nonperforated cylinder. (c) Test session in perforated cylinder.
its home cage (Figure 1(b)). In the test session, the same
procedure was repeated, except that no forced apnea was
applied (Figure 1(c)).
Rat behaviors were video recorded during test sessions
and scored by experimenters unaware of treatment variables.
The number and latencies of jumps were measured, together
with freezing time, deﬁned by immobility for at least 4s in
the interval of 0 to 4min.
2.5. Statistical Analyses. The Mann-Whitney U test was used
inordertocomparegroupeﬀects.Forrepeatedmeasures,the
Wilcoxon test was used. Data are expressed as the median
with limits of interquartile range values, and the level of
signiﬁcance is ﬁxed at P<0.05. The statistical analyses were
carried out with Statview 5.0 software (SAS Institute, Carey,
USA, 1992–1998).
3. Results
3.1. Subchronic Fluoxetine (5mg/kg, IP, 21 days). As shown
in Table 1, jumping prior to injections was not diﬀerent
betweenthegroups(U = 39.50; NS)butFLXadministration
decreased jumping compared with vehicle (U = 15.50; P =
0.03). While jumping frequency during baseline and test
sessions was stable in controls (z = 0.77; NS) it decreased in
FLX-treated rats (z = 2.37; P = 0.02). Likewise, immobility
time between the two groups did not diﬀer at baseline
(U = 24; NS), but was altered after drug administration4 Depression Research and Treatment
Table 1: Eﬀects of subchronic ﬂuoxetine (FLX) treatment (5mg/kg/21d, IP, n = 9, median with limits of interquartile range values). Mann-
Whitney U test: ∗P<0.05; ∗∗P<0.01 (FLX versus Vehicle). Wilcoxon-test: #P<0.05 (test versus baseline). Data were expressed as median
with limits of interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 9) FLX (n = 9) Vehicle (n = 9) FLX (n = 9)
Number of jumps 23 (9.8–37.3) 21 (16.5–31.5) 22 (10.5–27) 9∗# (0–12.8)
Latency before the ﬁrst jump (s) 15 (11.3–21.5) 14 (11.8–23.3) 16 (12.3–18) 27∗# (16.3–90)
Immobility (s) 140 (126.8–144.8) 59 (33.3–93.8) 164# (140–176.8) 70∗∗ (58.8–115)
Table 2: Eﬀects of subchronic imipramine (IMI) treatment (10mg/kg/14d, IP, n = 7, median with limits of interquartile range values).
Mann-Whitney U test: ∗P<0.05; ∗∗P<0.01 (IMI versus vehicle). Wilcoxon-test: #P<0.05 (test versus baseline). Data were expressed as
median with limits of interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 7) IMI (n = 7) Vehicle (n = 7) IMI (n = 7)
Number of jumps 24 (17.3–29) 22 (15.8–25) 28 (24.5–32.5) 15∗∗# (1.8–18.8)
Latency before the ﬁrst jump (s) 5 (3.3–11) 12 (6.3–24.3) 10 (7.3–18) 22∗∗# (19.8–74.5)
Immobility (s) 107 (93.5–117) 103 (93.5–150.8) 157# (124.8–182.5) 86∗ (33.5–128.5)
(U = 7; P = 0.003). The duration of immobility in baseline
and test sessions remained stable in FLX-treated rats (z =
0.65; NS), but increased in controls (z = 2.55; P = 0.01).
3.2. Subchronic Imipramine (10mg/kg, IP, 14 days). As seen
in Table 2, the groups did not diﬀer in terms of jumps prior
to injections (U = 21.50; NS). After injections, IMI-treated
rats displayed fewer jumps (U = 3; P = 0.006). The number
of jumps between baseline and testing was unchanged in
c o n t r o lr a t s( z = 0.85; NS), while it decreased in IMI-treated
rats (z = 2.03; P = 0.04). IMI-treated rats showed lower
immobilitytimeafterinjections(U = 6;P = 0.02),butnotat
baseline (U = 23; NS). Relative to baseline, immobility time
did not decrease signiﬁcantly in IMI-treated rats (z = 1.69;
P = 0.09) while it increased in controls (z = 2.37; P = 0.02).
3.3. Acute Diazepam (1mg/kg, IP). As seen in Table 3,
jumping frequencies did not diﬀer before or after injections
(U = 34.50; NS on baseline and U = 25; NS on test) and
r e m a i n e ds t a b l ei nb o t hg r o u p s( z = 0.42; NS for controls
and z = 1.72; NS for DZP-treated rats). No signiﬁcant
diﬀerence was observed in the duration of immobility
between the two groups during baseline and test session
(U = 37.5; NS on baseline and U = 21; NS, on test).
The duration of immobility remained stable in DZP-treated
rats between the two test sessions (z = 1.24; NS), while it
increased in control rats (z = 2.07; P = 0.04).
3.4. Acute Diazepam (3mg/kg, IP). As seen in Table 4,
duration of immobility, number of jumps, and jumping
latencies were not diﬀerent between vehicle and DZP groups
before treatment (U = 45, 39.5 and 46.5; NS, resp.). During
the test session, DZP-treated rats showed fewer jumps (U =
19.5; P = 0.02), the latency before the ﬁrst jump was higher
in this group (U = 19.5; P = 0.02), and immobility was
similar in both groups (U = 43.5; NS). This last parameter
increased signiﬁcantly between baseline and test session in
the vehicle and DZP-treated rats (z = 2.70; P = 0.007 and
z = 2.80; P = 0.005, resp.). The number of jumps remained
stable in control rats (z = 0.05; NS) but decreased in DZP-
treated ones (z = 2.70; P = 0.007). Jumping frequencies
remained stable in the two groups (z = 1.58; NS for controls
and z = 1.32; NS for DZP-treated rats).
3.5. Acute Clonazepam (1mg/kg, IP). As seen in Table 5,
duration of immobility, number of jumps, and jumping
latencies were not diﬀerent between vehicle and CZP groups
at baseline (U = 39.5, 36.5 and 31.5; NS, resp.). During
test session, CZP-treated rats displayed fewer jumps (U = 0;
P = 0.0003), the latency before the ﬁrst jump was higher
in this group (U = 13; P = 0.01), and immobility was
similar in both groups (U = 39; NS). The immobility
duration increased signiﬁcantly between baseline and test
session in both groups (z = 2.55; P = 0.01 for controls
and z = 1.95; P = 0.05 for CZP-treated rats). The number
of jumps remained stable in control rats (z = 0.41; NS),
while it decreased in CZP-treated rats (z = 2.67; P = 0.008).
Jumping frequency remained stable in controls (z = 0.21;
NS), whereas it increased in CZP-treated rats (z = 2.55;
P = 0.01).
3.6. Acute Fluoxetine (1mg/kg, IP). As seen in Table 6, the
results from acute FLX rats diﬀered from those of chronic
FLX animals. Jumping frequencies did not diﬀer before or
after injections (baseline: U = 34.50; NS and test: U = 38;
NS). While jumping frequency remained stable in controls
(z = 1.72; NS), it increased in FLX-treated rats (z = 2.31;
P = 0.02). The duration of immobility was not diﬀerent
between the two groups during baseline and test sessions
(baseline: U = 27; NS and test: U = 20; NS). However, thisDepression Research and Treatment 5
Table 3: Eﬀects of acute diazepam (DZP) treatment (1mg/kg, IP, n = 9, median with limits of interquartile range values). Wilcoxon-test:
#P<0.05 (test versus baseline). Data were expressed as median with limits of interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 9) DZP (n = 9) Vehicle (n = 9) DZP (n = 9)
Number of jumps 20 (15.5–23.5) 21 (15.3–28.8) 21 (17.5–23.3) 16 (12.3–22.3)
Latency before the ﬁrst jump (s) 17 (9.8–21.8) 15 (10.8–20.8) 13 (9.8–15.5) 21 (14.0–23.3)
Immobility (s) 106 (61.5–125.5) 101 (80.3–129.8) 121# (104.0–141.3) 90 (75.0–103.0)
Table 4: Eﬀects of acute diazepam (DZP) treatment (3mg/kg, IP, n = 9, median with limits of interquartile range values). Mann-Whitney
U test: ∗P<0.05 (DZP versus vehicle). Wilcoxon-test: ##P<0.01 (test versus baseline). Data were expressed as median with limits of
interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 9) DZP (n = 9) Vehicle (n = 9) DZP (n = 9)
Number of jumps 13.5 (12–17) 15.5 (8–28) 15 (10–19) 6∗## (4–14)
Latency before the ﬁrst jump (s) 15.5 (12–25) 23.5 (6–34) 11 (6–20) 28∗ (12–78)
Immobility (s) 84 (44–129) 85.5 (52–120) 129.5## (90–176) 130## (83–171)
variableincreasedinFLX-treatedratsandcontrols(z = 2.31;
P = 0.02 and z = 1.96; P = 0.05, resp.).
4. Discussion
Panic disorder is characterized not only by the presence
of unexpected and recurring panic attacks, but also by a
persistent and intense fear of further attacks. According to
Klein [61], Barlow’s psychological model of panic attacks
[62] suggests that they are related to an oversensitiveness to
CO2 [63, 64] which was later conﬁrmed in clinical-setting
studies [65]. This oversensitiveness could be explained by
a disturbed warning system involved in suﬀocation fear.
The false alarm leads to acute dyspnea, fear of impending
death, and an urgent need to ﬂee. Models of panic using
pharmacological agents, such as sodium lactate, 5% CO2,
or doxapram (respiratory analeptic), induce false suﬀocation
alarms, similar to those found in panic attack in terms
of physiological speciﬁcity and pharmacological reactivity
[38, 61, 66–70], and doxapram has been also used in the
rodent to determine its neuroanatomic basis [71].
The behaviors observed during panic attacks (ﬂight,
acute dyspnea) and the experimental conditions that we have
developed in the forced apnea test deﬁne the face validity of
our model. The combination of 30s forced apnea and cold
water appears necessary in our model to induce a chronic
stress reaction with signiﬁcant behavioral expression related
to paroxystic fear (unpublished data).
4.1. Task Parameters. Two stressors were used cold water and
restraint/immobilisation—in order to model extreme fear
conditions. Cold stress is a well-documented stressor in rats
[72–74]. For example, Jedema and Grace [75] demonstrated
activation of locus coeruleus neurons after exposure to low
temperatures in rats, thus central noradrenergic function
seems potentially modiﬁable in anxiety. Hyperventilation
and tachycardia occur before cold water immersion in
humans as a form of anticipatory anxiety [76], and the
“cold shock” itself causes an “inspiratory gasp,” hyperven-
tilation and secondary dyspnea, hypocapnia, tachycardia,
and hypertension [77]. These somatic symptoms are akin to
spontaneous manifestations during panic attacks [61].
The main purpose of our study was to create etho-
logical fear sequences through ﬂooding inside a rodent’s
burrow. Combined restraint and cold stressors are relevant
in inducing chronic stress conditions in rats [78, 79].
Restraint/immobilisation combined with cold water immer-
sion produces more behavioral alterations than immobilisa-
tion alone [80]. Likewise, Retana-M´ arquez et al. [59] showed
stressful eﬀects induced by immersion in cold water, both
acutely and chronically.
The number of jumps, the latency before the ﬁrst jump,
and the immobility time were assessed in male adult rats
exposed to our model. In placebo controls, paroxysmic
fear induced both active (jumps) and passive (immobility)
reactions. At baseline, all rats jumped every 3.5s during
vaporisation, indicating that this is a typical reaction to a
proximal threat. The same animals spent 87.5% of their time
in a freezing posture during application of water beside the
cylinder, suggesting that this models a typical reaction to a
distant threat. Richter-Levin [33]u s e dw a t e rt r a u m ai na
model of PTSD. Similarly, classical conditioning is probably
involved in PD [39]; Bouwer and Stein [35] showed a
relationship between PD and near drowning. Taken together,
these data support the idea that severe anxiety disorders and
panic attacks may be mimicked in laboratory settings and
still be ethically acceptable because of their brief duration.
4.2. Subchronic Fluoxetine and Imipramine. Subchronic
administration of FLX and IMI caused similar eﬀects.
Both substances decreased jumps and immobility time and
increased time latency before the ﬁrst jump. All these three
eﬀects are attributable to their anxiopanicolytic proper-
ties. They concur with those of PD paradigms. With the
MDTB, Griebel et al. [56] reported a signiﬁcant decrease in6 Depression Research and Treatment
Table 5: Eﬀects of acute clonazepam (CZP) treatment (1mg/kg, IP, n = 9, median with limits of interquartile range values). Mann-Whitney
U test: ∗P<0.05; ∗∗P<0.01 (CZP versus vehicle). Wilcoxon-test: #P ≤ 0.05; ##P<0.01 (test versus baseline). Data were expressed as
median with limits of interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 9) CZP (n = 9) Vehicle (n = 9) CZP (n = 9)
Number of jumps 17 (9.75–21.75) 15 (11–17) 18 (15.25–20.5) 3∗∗## (2–8)
Latency before the ﬁrst jump (s) 14 (6.5–35.75) 12 (4.5–19.5) 10 (7.25–31) 68∗# (20.5–75)
Immobility (s) 90 (50–133.5) 85 (65.25–115) 130# (92–162) 125# (104–145.5)
Table 6: Eﬀects of acute ﬂuoxetine (FLX) treatment (10mg/kg, IP, n = 9, median with limits of interquartile range values). Wilcoxon-test:
#P<0.05 (test versus baseline). Data are expressed as median with limits of interquartile range values.
Measures
Baseline (before treatment) Test (after treatment)
Vehicle (n = 9) FLX (n = 9) Vehicle (n = 9) FLX (n = 9)
Number of jumps 17 (13.5–19.5) 15 (13.3–17.8) 19 (16.8–24.8) 21# (19.0–22.5)
Latency before the ﬁrst
jump (s) 19 (12.8–27.3) 20 (14.8–29.5) 16 (13.0–17.8) 14# (4.8–19.5)
Immobility (s) 85 (68.0–98.0) 97 (81.5–114.8) 108# (93.8–126.3) 139# (115.0–159.3)
the number of mouse escapes from a predator (anaesthetised
rat) after FLX treatment for 21 days at the dose of 5mg/kg IP.
Likewise, in the UEEPM [9], the number of escapes of FLX-
treated rats (10mg/kg, PO) was lower than that of controls.
Moreover, Vargas and Schenberg [81] showed that 3-week
FLX treatment at the dose of 5mg/kg, IP, increased dPAG
stimulation thresholds causing escape attempts. Similarly,
various selective serotonin reuptake inhibitor (SSRIs), such
as citalopram, FLX, paroxetine, sertraline, and escitalopram,
reduced the ﬂight-like escape behavior produced by dPAG
electrical stimulation in the rat [12, 13]. Borelli et al.
[26] found that 2-week FLX treatment at 5mg/kg, IP,
increased dPAG stimulation thresholds for freezing, but not
escape attempts. The latter data, as our own, indicate that
freezing is a relevant measure in animal models of extreme
anxiety, although the main characteristics of panic is the
ﬂight response. These results suggest that FLX decreases
freezing responses in rats under intense fear conditions.
They are also consistent with the results obtained by Santos
et al. [27]. Moreover, the CCK-4 (cholecystokinin type 2
(CCK(2)) receptor agonist) intradorsolateral periaqueductal
gray injection facilitated the expression of both freezing and
escape behaviors [14]. These data support the hypothesis
that both locomotor reactions are closely related to panic
behaviors and should be taken into account given their high
expression levels in our model.
At the pharmacological level, chronic administration
of SSRIs treatments appears to sensitize 5-HT1A receptors
in the dPAG and supports the idea that facilitation of 5-
HT1A receptor-mediated neurotransmission in the dPAG is
implicated in the pharmacotherapy of PD [13, 16, 17].
Finally, FLX, paroxetine, and sertraline SSRIs are also
eﬀective in diﬀerent models of PTSD in rats [82–84].
Tricyclicagents,suchasIMIat10mg/kg/14d,hadsimilar
eﬀects to those obtained with FLX at 5mg/kg/21d in terms
of escape attempts and freezing duration. In the MDTB
“predator avoidance test,” IMI at 5 and 10mg/kg for 21
days decreased mouse avoidance distance and frequency of
escapes from the rat [56] .L i k e w i s e ,J a c o be ta l .[ 85] showed
that a 3-week IMI treatment at 15mg/kg, IP, produced an
enhancement of the antiaversive eﬀect of 5-HT receptor
agonists locally injected into the PAG. Blanchard et al. [86]
observed a decrease of freezing in rats after presentation of
a cat after 3-week IMI treatment at 15mg/kg, IP. Our results
are reminiscent of successful PD and PTSD treatments [40–
47] after chronic administration of IMI or FLX in clinical
studies.
4.3. Acute Benzodiazepines. DZP is not considered to be as
eﬀectiveasotherantipanicagents[87].At1mg/kg,DZPonly
prevents the increase of immobility after fear conditioning
and has no eﬀect on escape attempts. Likewise, no eﬀect
was observed after PAG stimulation with DZP at the doses
of 1, 2, and 4mg/kg, IP [26] and one-way escape was not
aﬀected by DZP at 0.5, 1, 2, and 4mg/kg, IP in the elevated
T-maze [11]. However, Griebel et al. [55] found a panicolytic
eﬀect with DZP at 3mg/kg in the MDTB but not at 0.5 and
1 m g / k g ,I P .I no u rm o d e l ,D Z P ,a t3 m g / k g ,I P ,d e c r e a s e s
the number of jumps, without aﬀecting the duration of
immobility as it was previously noted with a lower dose.
Our interpretation of these results is that, at 1mg/kg, IP,
DZP only acts on anticipatory anxiety (freezing), without
interactingwithpanic reaction(jumps),whereas,at3mg/kg,
IP, its sedative eﬀects mask its potential eﬀect on anxiety,
but is able to decrease panic-related symptoms. Li et al. [88]
evaluated the eﬀects of DZP in a PTSD model—consisting of
a2-dayfootshock(0.8mA,10s)periodfollowedby3weekly
situational reminders. After 26-day IP administration, DZP
at a low dose of 0.25mg/kg, but not at 4mg/kg, reduced
behavioral deﬁciencies. Additional data is therefore neededDepression Research and Treatment 7
concerning possible benzodiazepine eﬀects at variable doses,
suchassubchronicadministrationandawiderrangeofdoses
used in our paradigm. Although benzodiazepines are used in
theshort-termtreatmentofPTSD,long-termtreatmentwith
these molecules is not eﬀective [89–91].
In addition, a 3-day treatment with CZP at 5mg/kg, IP,
completely blocked the eﬀects of bicuculline following its
infusionindorsomedialhypothalamus[19].AfteracuteCZP
administration at 0.1, 0.56, and 1mg/kg, IP, Jenck [92]n o t e d
that it reduced, in a dose-related manner, aversive behaviors
induced by dPAG stimulation. In the MDTB, CZP single
doses of 0.3 and 1mg/kg, IP, decreased avoidance distance
and avoidance reactions [86]. Our results are consistent with
those of Blanchard regarding DZP admnistration at 3mg/kg,
IP, but not following FLX and IMI administration. In our
study, CZP only aﬀected the number of jumps. Unlike our
resultsfollowingDZPadmnistration,asigniﬁcantincreaseof
latency before the ﬁrst jump was observed between baseline
and test after CZP intake. This eﬀect can be explained by
CZP’s superior eﬃcacy on panic attack symptoms compared
to DZP. Conversely, CZP did not prevent the increase of
immobility after forced apnea. These results are consistent
with the clinical data suggesting that CZP reduces panic
attack intensity but has no eﬀect on anticipatory anxiety in
PD [93].
At the pharmacological level, alprazolam facilitates 5-
HT1A receptor-mediated neurotransmission in the dPAG,
like SSRIs [15]. This could partially explain the similar
eﬀects obtained by SSRIs, high-potency benzodiazepines,
suchasalprazolamandclonazepam,andlow-potencybenzo-
diazepine, such as diazepam at sedating doses, on ﬂight-like
escape behaviors.
4.4. Acute Fluoxetine. The panicogenic eﬀect of acute FLX is
a well-known parameter in clinical practice [49] or in animal
experimentation [3]. In the MDTB, acute FLX increased
avoidance distance [56]. However, in the UEEPM, acute FLX
did not increase rodent escape behavior [9], and in dPAG
stimulation models, acute FLX either attenuated escape
behaviors [94]o rh a dn oe ﬀect on these behaviours [26].
In our model, FLX at 10mg/kg, IP, had a panicogenic eﬀect
which was measured via the comparison of two ethological
variables between baseline and test session in FLX-treated
rats, that is, increase of the number of jumps and decrease
of latency before the ﬁrst jump.
In conclusion, our model is an innovative behavioral
paradigmthatmayimproveinvestigationofanxietydisorder.
Our results are consistent with the hypothesis that eﬀective
d r u g sf o rG A Da n dP D / P T S Dh a v ed i ﬀerential eﬀects on
speciﬁc defensive behaviors in rats. Antidepressant agents,
such as IMI and FLX, counteract anticipatory anxiety and
panic symptoms, whereas high potency benzodiazepines or
lowpotencybenzodiazepinesatsedatingdosesonlyaﬀectthe
panic-related symptoms.
Clinical observations also seem to converge with our
results. Indeed, benzodiazepines immediately decrease panic
attack-related anxiety symptoms; however, antidepressant
drugs remain the gold standard treatment for the long-term
management of PD [95].
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